Home

IN ORDER TO RECOGNIZE AND FIGHT TUMOR CELLS.

Chimeric Antigen Receptor T cells (CAR T), developed by Prof. Zelig Eshhar (Weizmann Institute of Science), is a promising therapy that comprises the genetic engineering of T cells in order to make them express artificial receptors endowing them with the ability to recognize and attack tumor cells.

CAR T treatment is successfully applied in certain types of hematological malignancies like Acute Lymphoblastic Leukemia (ALL) and Diffuse Large B Cell Lymphoma (DLBCL).

Despite that, no encouraging results have been obtained in solid tumors, mostly due to poor efficiency and high toxicity issues.

THE NEED

One of the key challenges that faces the CAR T therapy is the “on-target/off tumor toxicity” caused by target antigen expression on normal cells which results in CAR T-mediated killing of healthy tissue

Therefore, treating patients with solid tumors with CAR T may cause severe side effects, including death.

OUR
SOLUTION

CTG’s mission is to provide a solution to the on-target/off tumor toxicity: our company designed a series of genetic ‘On Switches’ in order to circumscribe the immune response exclusively to the tumor microenvironment.